(Q37780040)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

K Potthoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Hofheinz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J C Hassel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

M Volkenandt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

F Lordick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J T Hartmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

M Karthaus

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

H Riess

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

H P Lipp

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Hauschild

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Wollenberg

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

13 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

524-535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20709812%20AND%20SRC:MED&resulttype=core&format=json

Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

The EGF/TGF alpha receptor in skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Mechanisms of cutaneous toxicities to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Cutaneous side effects of EGFR inhibitors--appearance and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Cutaneous side effects of EGF-receptor inhibition and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Tetracyclines: nonantibiotic properties and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Anti-inflammatory activity of tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

Skin toxicities associated with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387

The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ387